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Abstract
Background:  Antibodies targeting variant antigens expressed on the surface of Plasmodium
falciparum infected erythrocytes have been associated with protection from clinical malaria. The
precise target for these antibodies is unknown. The best characterized and most likely target is the
erythrocyte surface-expressed variant protein family Plasmodium falciparum erythrocyte membrane
protein 1 (PfEMP1).
Methods: Using recombinant proteins corresponding to five domains of the expressed A4 var
gene, A4 PfEMP1, the naturally occurring antibody response was assessed, by ELISA, to each
domain in serum samples obtained from individuals resident in two communities of differing malaria
transmission intensity on the Kenyan coast. Using flow cytometry, the correlation in individual
responses to each domain with responses to intact A4-infected erythrocytes expressing A4 PfEMP1
on their surface as well as responses to two alternative parasite clones and one clinical isolate was
assessed.
Results: Marked variability in the prevalence of responses between each domain and between each
transmission area was observed, as wasa strong correlation between age and reactivity with some
but not all domains. Individual responses to each domain varied strikingly, with some individuals
showing reactivity to all domains and others with no reactivity to any, this was apparent at all age
groups. Evidence for possible cross-reactivity in responses to the domain DBL4γ was found.
Conclusion:  Individuals acquire antibodies to surface expressed domains of a highly variant
protein. The finding of potential cross-reactivity in responses to one of these domains is an
important initial finding in the consideration of potential vaccine targets.
Published: 16 August 2008
Malaria Journal 2008, 7:155 doi:10.1186/1475-2875-7-155
Received: 2 May 2008
Accepted: 16 August 2008
This article is available from: http://www.malariajournal.com/content/7/1/155
© 2008 Mackintosh et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Malaria Journal 2008, 7:155 http://www.malariajournal.com/content/7/1/155
Page 2 of 10
(page number not for citation purposes)
Background
Maintaining Plasmodium falciparum infections whilst lim-
iting morbidity and mortality is a feature of the non-ster-
ile immunity acquired by individuals living in malaria
endemic areas. Studies whereby antibodies were passively
transferred from immune to non-immune individuals
suggested this immunity is, at least in part, antibody-
mediated [1,2]. Humans exposed to malaria can mount
an antibody response to many parasite antigens including
those present on the sporozoite, merozoite and those on
the surface of the infected erythrocyte [3-5]. Parasite
induced antigens on the infected red cell surface are
potentially important targets for protective immunity
because they are exposed for long periods of the erythro-
cytic cycle and serve critical biological functions [6]. Fol-
lowing infection children mount antibodies directed
against the infected erythrocyte surface, specific to the
infecting isolate [7-10] and such antibodies are associated
with protection from subsequent clinical malaria with the
homologous parasite [8].
The most extensively characterized of the proteins
expressed at the infected red cell surface are the products
of the var genes, Plasmodium falciparum erythrocyte mem-
brane protein 1, (PfEMP1) [11]. PfEMP1 is a family of
extracellular, highly polymorphic and clonally variant
adhesion molecules [12-16]. They are expressed on the
surface of the red cell at around 18 hours after invasion
and remain present throughout the second half of the
intra-erythrocytic cycle [12]. They exhibit a domain struc-
ture and the domains bear homology to the cysteine-rich
binding domains of varied Plasmodium molecules
involved in the binding to and invasion of erythrocytes;
EBA-175, the P. falciparum glycophorin A receptor and the
Plasmodium vivax and  Plasmodium knowlesi ligands that
allow invasion of Duffy blood-group positive erythrocytes
[17-19]. These domains are called Duffy-binding like
domains (DBL) and they are interspersed with regions
containing multiple cysteine residues termed the cysteine-
rich interdomain regions (CIDR).
Using a panel of recombinant proteins corresponding to
the domains of one particular PfEMP1 protein, A4
PfEMP1 from the A4 laboratory parasite line, domain-spe-
cific antibodies prior to the transmission season in two
communities in Kenya with differing transmission charac-
teristics were measured. The presence of these antibodies
was related to the likelihood of experiencing clinical
malaria during the subsequent transmission season. It was
shown that humans are capable of mounting anti-PfEMP1
domain-specific antibodies and that the prevalence of
these antibodies is related to exposure. Furthermore
responses to one recombinant domain, DBL4γ, show evi-
dence of cross-reactivity or perhaps are being directed at a
more conserved epitope.
Materials and methods
Study population
This work was carried out at the Kenya Medical Research
Institute, Centre for Geographic Medicine Research Coast
situated at Kilifi District Hospital, 50 km north of Mom-
basa on the coast of Kenya. The hospital serves around
240,000 people living north and south of an ocean creek.
Individuals investigated during these immuno-epidemio-
logical studies were resident in two sites in Kilifi District
(within 20 km of each other), Chonyi and Ngerenya.
These study sites have been described in detail elsewhere
[20]. Inhabitants of these areas are predominantly
Mijikenda, sharing similar beliefs and customs. Residents
of Ngerenya receive, on average 10 infective bites/person/
year, [21], whereas residents of Chonyi have an estimated
50 bites/person/year [22]. The annual incidence of clini-
cal malaria among the two communities varied with both
age and area. In children less than one year of age, the
incidence was higher in Chonyi than in Ngerenya (IRR
1.56 [95% CI 1.18–2.06]p = 0.002), there was no differ-
ence between the two areas in children aged 1–3 years and
in those aged 4 – 19 years the incidence was higher in
Ngerenya (IRR 0.45 [95% CI 0.4–0.51]p = 0.001) [20].
Sample collection
Sera collection and active surveillance were conducted as
part of a study examining the clinical epidemiology of
malaria under differing transmission conditions[20]. In
brief, serum was collected in October 2000 from 1,222
individuals resident in both areas aged between six
months and 85 years. A blood slide was prepared for every
individual in the cohort at the time of serum collection in
order to define their pre-clinical surveillance status as par-
asite positive or negative. All individuals included in this
study were asymptomatic and afebrile at the time of cross-
sectional survey. The cohorts were then followed for evi-
dence of malaria by weekly active surveillance for fever.
Malaria was defined as a febrile episode with an axillary
temperature greater than 37.5°C and a parasitaemia of
greater than 2500 parasites/μl above one year of age, and
fever plus any parasitaemia below a year. These have been
determined to be sensitive and specific malaria case-defi-
nitions in both study communities[20]. Twenty non-
malaria exposed control sera were collected from Oxford,
UK.
Parasites
These experiments were performed using a laboratory
clone of parasite, A4. This particular parasite was chosen
for a number of reasons. There exists a monoclonal anti-
body, BC6, which allows in vitro selection of A4 parasites
expressing specifically A4 PfEMP1[23]. A4 PfEMP1 has a
well-described and classified sequence already published
with established domain boundaries and it displays a
common cytoadherent phenotype, binding to both CD36
and ICAM-1 [24].Malaria Journal 2008, 7:155 http://www.malariajournal.com/content/7/1/155
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The parasite clone A4 having undergone prior selection
with BC6 is denoted A4U. In addition two further labora-
tory clones, A4 40-cycle (parasites of the A4 lineage which
have been left in culture for 40 cycles with no selection)
and 3D7, and one clinical isolate, P1, obtained from a five
year old child admitted to Kilifi District Hospital with
moderately severe malaria were used to investigate anti-
body reactivity against the intact infected erythrocyte by
flow cytometry. Using the monoclonal antibody BC6,
flow cytometry demonstrated expression of the A4 var
gene of between 88–95% in A4U parasites and between
11 and 25% in A4-40 cycle parasites. There was no recog-
nition of either 3D7 or P1 with BC6.
Expression of A4 PfEMP1 domains; DBL1α, DBL2β, 
CIDR1α, DBL4γ, DBL5β in BL21-CodonPlus-Ril E. coli
For secreted, IPTG-inducible expression in BL21-Codon-
Plus-Ril Escherichia coli (Stratagene UK), vector pMal-c2x
(New England Biolabs) was used. Primers for PCR ampli-
fication were as follows (Accession number L42244):
DBL1α forward 5'-CATGGTAGGGAGGATCCT, reverse 5'-
CCCCAAGCTTGCCTATTCCGTATGAGAAAATG includ-
ing the restrictions sites SmaI and HindIII respectively;
CIDR1α forward 5'-TCCCCGGGGCAGGTGGATTATG-
TATATTCG, reverse 5'-CCCCTGCAGCTATGAATCAC-
CAATAGCATTGG including restriction sites SmaI and PstI
respectively; DBL2β forward 5'-CTCCCCGGGACGAAC-
CAATATTCCAATGC, reverse 5'-CCTCTAGACTAGCACA-
CATCCAACTTGGTGTC including restriction sites SmaI
and XbaI respectively; DBL4γ forward 5'-GCTCCCCG-
GGTGCAATACAAAATATTATCCAAC, reverse 5'-CCCG-
CAAGCTTGCTACGAAGCAAATGTACTGTC including
restriction sites SmaI and XbaI respectively; DBL5β for-
ward 5'-GCTCCCCGGGGCTTCGAATTGTGAAC, reverse
5'-CCTCTAGACTAGATTTCGGATCGTTATTACTCG.
(Domains DBL3δ and CIDR2 of the A4 var gene were una-
ble to be satisfactorily cloned despite many attempts).
Amino acid numbering of each recombinant domain:
DBL1α 81–480, CIDR1α 590–841, DBL2β 832–1229,
DBL4γ 2006–2437, DBL5β 2435–2802. PCR fragments
corresponding to each domain were purified using a
QIAquick PCR purification kit (Qiagen, Hilden, Ger-
many) and were ligated into pCR 2.1 vector (Invitrogen),
containing the α-peptide of b-galactosidase to allow blue-
white selection in the presence of 5-bromo-4-chloro-3-
indolyl-b-D-galactoside (X-Gal). Sub-cloning efficiency
cells DH5α were transformed and positive recombinant
clones were identified by loss of α-complementation.
Transformants were checked, by PCR performed with vec-
tor-specific primers, for the presence of domain-specific
DNA and the plasmid DNA was purified using Wizard
Plus SV Minipreps (Qiagen, Hilden, Germany). Purified
pCR 2.1 plasmids containing individual domains were
digested with the correct restriction enzymes and ligated
into pMal-c2x vector (New England Biolabs), which had
been previously cut appropriately. DH5α cells were again
transformed and blue-white screening as before identified
positive recombinant clones. DNA sequencing using an
ABI 373 Prism automated sequencing system with a Big
Dye terminator sequencing kit (Applied Biosystems, Fos-
ter City, California) determined nucleotide sequences of
the inserts. Sequence identities were confirmed by BLAST
analysis. For protein expression BL21-CodonPlus-Ril
competent cells (Stratagene) were used. The transformed
cells were grown in Luria-Bertani medium with 0.2% glu-
cose, ampicillin (50 μg/mL) to maintain the expression
plasmid and chloramphenicol (50 μg/mL), to an optical
density at 600 nm (OD600) of 0.3 to 0.5 at temperatures
between 25°C and 37°C depending on the individual
construct. Each culture was then induced to express the
MBP-DBL/CIDR fusion proteins in the presence of 0.1
mM isopropyl-β-D-thiogalactoside (IPTG). The samples
were spun and the pellet re-suspended in 1 M Tris lysis
buffer. The cells were disrupted by sonication (12 pulses ×
1 min). After spinning each MBP-fusion protein was puri-
fied by chromatography on amylose resin as recom-
mended by the manufacturer (New England Biolabs),
using 100 mM maltose for elution. After purification, the
protein obtained was stored in the following buffer: 10
mM Tris-HCl, pH 7.4, 0.2 M NaCl, 10 mM β-mercaptoeth-
anol, 1 mM EDTA at -80°C. Protein purity was deter-
mined by sodium dodecyl sulphate-polyacrylamide gel
electrophoresis with 10% polyacrylamide and quantity
was estimated by a protein assay kit (Bio-Rad, Munich,
Germany) as recommended by the manufacturer.
Enzyme-linked immunosorbant assay (ELISA)
After checkerboard assays to determine the optimal coat-
ing concentration, 200 ng of DBL2β and DBL4γ and 400
ng of DBL1α, CIDR1α and DBL5β were coated onto indi-
vidual wells in Nunc transparent, flat-bottomed 96 well
plates (Nunc Technology) in 100 μl phosphate buffered
saline (PBS). An equivalent molar concentration of MBP
alone was coated as a control. In addition schizont extract
of the A4 strain of Plasmodium falciparum was produced
and coated onto plates in PBS using the methods
described by Ndungu et al [25]. The plates were incubated
overnight at 4°C, washed in PBS with 0.05% Tween 20
and blocked with 200 μl blocking buffer (10% skimmed
milk in PBS with 0.5% Tween 20) for 1 hour at 37°C. The
plates were washed again as before and 100 μl of human
sera (diluted 1:100 with blocking buffer) was incubated in
duplicate for 1 hour at 37°C. The wells were again washed
and 100 μl of HRP-conjugated rabbit anti-human IgG
(Dako Ltd.), at a dilution of 1:5000 was added and the
plates incubated again for 1 hour at 37°C. Detection was
by the addition of O-phenylenediamine/H2O2 (Sigma)
for 15 minutes in darkness. The mean OD value, taken at
492 nm, was calculated for each sample after correction
for binding to MBP alone. A serum was scored as positiveMalaria Journal 2008, 7:155 http://www.malariajournal.com/content/7/1/155
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if the corrected OD value was higher than the mean + 3 SD
of 20 negative control sera from UK residents who had
never been exposed to malaria. All sera were screened in
duplicate and a selection repeated at a later date. OD val-
ues were standardized against a pre-screened high positive
standard on each plate. Please see additional files 1 and 2
for the mean OD values for the positive standards on each
plate and for the range of OD values obtained with sera
from 20 non-malaria exposed UK donors respectively.
Flow cytometry
Using parasite clones A4U, A4-40 cycle and 3D7 and the
clinical isolate, denoted P1, cryo-preserved trophozoite-
infected erythrocytes at between 1 and 5% parasitaemia
were thawed through the sequential restoration of isoto-
nicity [26]. They were washed twice in RPMI and the pellet
was resuspended at 1% haematocrit in 0.1% bovine
serum albumin/phosphate-buffered saline (0.1%BSA/
PBS). 1 μl of human serum was pipetted into separate
wells of a 96-well U-bottomed plate (Nunc Technology)
and 9 μl of the infected erythrocyte cell suspension was
added to each well giving a final test serum concentration
of 1:10. The reaction mixture was incubated at room tem-
perature for 1 hour, following which the cells were spin
washed three times with 0.1%BSA/PBS. The cells were
then resuspended in 25 μl 0.1%BSA/PBS containing the
secondary antibody, rabbit anti-human IgG at a concen-
tration of 1:100. Again the reaction mixture was incubated
for 1 hour at room temperature after which a further three
washes were performed as before. Finally 25 μl of
0.1%BSA/PBS containing a 1:100 dilution of swine anti-
rabbit IgG coupled to FITC and 10 μg/ml of ethidium bro-
mide was added to each well. A further incubation at
room temperature in darkness, for 1 hour was done after
which, following a further series of washes; at least 1,000
infected erythrocytes were counted on an EPIC/XL flow
cytometer (Coulter-electronics, UK).
Reactivity against the infected erythrocyte surface was
scored as mean fluorescent intensity using the method of
Williams et al [27]. In detail, mean fluorescence of para-
site-infected erythrocytes was determined using the for-
mula:
(d-c)-(b-a)
a = the mean fluorescence intensity (MFI) of uninfected
erythrocytes following incubation in negative control
plasma; b = MFI parasitized erythrocytes following incu-
bation in negative control plasma; c  = MFI uninfected
cells incubated in immune plasma or test antibody and d
= MFI parasitized erythrocytes incubated in immune
plasma or test antibody.
Statistical analysis
All statistical analyses were performed using Stata version
8 (Statacorp, TX, USA). To investigate the relationship
between parasite status at the time of cross-sectional bleed
and subsequent antibody levels, a multiple linear regres-
sion model, controlled for age, expressed as a factor of 6
months duration, location and exposure (estimated by
responses to schizont extract) was performed. The results
are expressed as coefficients describing the difference in
antibody levels attributable to parasites.
Significant differences in two or more continuous varia-
bles were calculated using the Wilcoxon rank sum test.
The Chi-squared test for trend was used to assess a trend
across groups.
In a randomly selected subgroup of individuals (148 from
Chonyi and 142 from Ngerenya, all ages represented),
total IgG responses to erythrocytes parasitized with A4U,
A4-40 cycle, 3D7 and P1 were also measured using flow
cytometry. The correlation of responses to each individual
domain with responses to the parasitized erythrocyte sur-
face was assessed using the Spearman rank correlation
coefficient.
In order to investigate any association of domain-specific
antibody responses with protection from clinical malaria,
initially the univariate association between detectable
serum IgG to each antigen (measured as OD), and
whether or not the individual had an episode of clinical
malaria during the subsequent six months was investi-
gated by fitting the continuous variable against a bino-
mial distributed outcome using logistic regression. As
antibody reactivity is known to increase with exposure, a
multiple logistic regression was then performed with age,
location and reactivity to schizont extract, as a marker of
exposure, included as co-dependent variables. Results are
expressed as odds ratios per 10 fold increase in antibody
levels.
Results
Naturally occurring antibody responses to recombinant 
PfEMP1 domains
Evidence for age-associated acquisition of domain-spe-
cific IgG was apparent for responses against recombinant
domains DBL1α and DBL4γ in both Ngerenya and Cho-
nyi (Figure 1). No appreciable increase in antibody acqui-
sition with age was seen with CIDR1α, in either area and
with responses to both DBL2β and DBL5β, the trend for
increasing acquisition of responses with age was signifi-
cant in the higher of the two transmission areas, Chonyi
Noticeable differences could be seen in the response to
the different PfEMP1 domains. For example it is clear that
a greater proportion of individuals recognize DBL1α andMalaria Journal 2008, 7:155 http://www.malariajournal.com/content/7/1/155
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Proportion of individuals in each age group recognizing recombinant domains Figure 1
Proportion of individuals in each age group recognizing recombinant domains. Sera from 1222 individuals older 
than six months, was tested for reactivity against each recombinant protein in turn using ELISA. Responses were scored as pos-
itive if the mean OD obtained was greater than the mean OD plus 3 standard deviations of a panel of 20 non-malaria exposed 
donors. The solid grey bars refer to individuals resident in Chonyi and the hatched bars to individuals resident in Ngerenya. a) 
DBL1α, b) CIDR1α, c) DBL2β, d) DBL4γ, e) DBL5β. P-values given are chi-squared for trend, C = Chonyi N = Ngerenya.
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DBL4γ than the other three domains with overall 30.8%
(95% CI 26.2 – 35.8%) and 32.5% (95% CI 27.9 –
37.3%) of individuals recognizing DBL1α and DBL4γ
respectively, compared to 18.8% (95% CI 13.9 – 24.3%),
21.2% (95% CI 16.4 – 26.7%) and 19.6% (95% CI 14.7
– 25.2%) for CIDR1α, DBL2β and DBL5β respectively (p
< 0.0001 for comparison of overall recognition of DBL1α
or DBL4γ with any other domain Wilcoxon ranksum).
There was a clear increase in proportion of responders and
rate of acquisition of responses in Chonyi compared to
Ngerenya. For example with DBL4γ the maximum
response in Chonyi occurs in the 16 – 20 year age group
with 61.8% (95% CI 43.6 – 77.8%) of individuals in this
age group recognizing this domain. This is compared to
the maximum response in Ngerenya against the same
domain, which did not occur until the 51 – 85 year age
group and was lower at 56.5% (95% CI 34.5 – 76.8%).
Acquisition of antibody responses against DBL4γ was
more rapid in Chonyi where, by the age of 8 – 9 years
45.2% (95% CI 32.5 – 58.3%) of children responded
compared to 18.6% (95% CI 9.70 – 30.9%) of children
resident in Ngerenya (p = 0.0019 Wilcoxon ranksum). For
responses against DBL1α, the situation was different with
acquisition in both areas continuing throughout adult-
hood. The maximum response in both areas did not occur
until the 51 – 85 year age group although as with DBL4γ,
the maximum response was greater in Chonyi, 67.6%
(95% CI 50.2 – 81.9%) than in Ngerenya at 43.5% (95%
CI 23.2 – 65.5%) although this difference was not signifi-
cant. Overall a greater proportion of individuals resident
in Chonyi showed evidence of reactivity against DBL1α
and DBL4γ but not CIDR1α, DBL2β or DBL5β. The two-
sample Wilcoxon rank sum for the differences in response
between the two locations gave the following significance
values: DBL1α p = 0.0128, CIDR1α p = 0.0594, DBL2β p
= 0.0774, DBL4γ p = 0.0000 and DBL5β p = 0.3848.
Individual variation in antibody responses to recombinant 
domains of A4-PfEMP1
461 individuals recognized none of the domains tested
and of these 57.7% were resident in Ngerenya and 42.3%
in Chonyi. Of these 461 individuals, 61.2% were aged less
than 10 yrs. 350 individuals only recognized 1 domain to
the exclusion of all the others, 160 of these individuals
(45.7%) were aged less than 10 years. Of those only rec-
ognizing one domain, 26.6% recognized DBL1α only,
11.7% recognized DBL2β, 12.7% recognized CIDR1α,
37.4% DBL4γ only and 11.4% DBL5β only, making
DBL4γ significantly more likely to be the single domain
recognized (OR 1.67 (95% confidence interval 1.24 –
2.24) p = 0.001). Only 38 individuals recognized all 5
domains tested (3.12% of the whole cohort), of these 24
(63.2%) were aged over 10 yrs.
Overall the number of domains recognized increased with
age in both areas (Figure 2). In six of the age groups, indi-
viduals resident in Chonyi recognized a significantly
greater number of domains.
Association of asymptomatic parasitaemia and anti-
A4PfEMP1 antibody responses
It has previously been noted that antibody responses to a
number of parasite antigens are enhanced in younger
individuals who are parasitized at the time of blood sam-
pling [28-30]. Using a logistic regression analysis taking
into account age, exposure (as estimated by responses to
whole schizont extract) and location, and restricting the
analysis to those less than 10 years, individuals with par-
asites in their blood at the time of bleed were significantly
more likely to recognize any recombinant domain com-
pared to recognizing no domains (OR 1.94 (95% CI 1.34
– 2.83) p < 0.001). Furthermore, using an ordered logistic
regression, with the same confounding variables, those
children parasite positive at the time of cross-sectional
bleed were more likely to recognize a greater number of
domains (OR 1.66 (95% CI 1.17 – 2.34) p = 0.004).
Using a multiple linear regression model, the effect of
asymptomatic parasitaemia on the OD value obtained for
each domain after controlling for age, location and expo-
sure was determined. Having detectable parasites at cross-
sectional bleed was associated with significantly higher
OD values for domains DBL1α, DBL2β and CIDR1α
(Table 1). There was no effect on antibody reactivity to
DBL4γ or DBL5β.
Correlation of responses to recombinant domains with 
responses to the surface of erythrocytes infected with A4 
parasites selected to express A4-PfEMP1
Figure 3 outlines the prevalence of responses to A4U
measured by flow cytometry. Acquisition of responses
Mean number of domains recognised with age Figure 2
Mean number of domains recognised with age. Graph 
shows mean number of domains, plus upper 95% confidence 
limits, recognized by individuals in each age group. The dark 
grey bars refer to individuals in Chonyi and the hatched bars 
to individuals resident in Ngerenya. *=P-value <0.05 (Wil-
coxon Ranksum).
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with age is demonstrated. Using Spearman's rank correla-
tion coefficient to assess significance, only responses to
DBL1α and DBL4γ were positively correlated with
responses to the surface of erythrocytes infected with A4
parasites selected to express A4-PfEMP1, A4U (DBL1α v
A4u Spearman's rho = 0.1263 P = 0.0315; DBL2β v A4u
Spearman's rho = 0.0462 P  = 0.4331; CIDR1α v A4u
Spearman's rho = -0.1281 P = 0.0292; DBL4γ v A4u Spear-
man's rho = 0.2866 P < 0.0001; DBL5β v A4u Spearman's
rho = 0.0376 P = 0.5239) In an attempt to control for
exposure accounting for any positive correlation, a multi-
ple linear regression model was performed with age, loca-
tion, parasite status and exposure (estimated by responses
to schizont extract) as independent variables, for each of
the pairs. Using this model, only the correlation between
responses to DBL4γ and A4u reached significance (Coeffi-
cient 0.332 (95% CI 0.101 – 0.563) P = 0.005).
In addition individual responses to each recombinant A4-
PfEMP1 domain were correlated against antibody
responses to two further parasite clones and one clinical
isolate as measured by flow cytometry; A4-40 cycle, 3D7
and a clinical isolate P1. Additional file 3 outlines the
prevalence of responses to each of these parasites as meas-
ured by flow cytometry. Responses to DBL4γ recombinant
protein correlated significantly with responses to erythro-
cytes infected with each of the parasites tested (DBL4γ v
A4-40cycle Spearman's rho = 0.3909 p < 0.001; DBL4γ v
P1 Spearman's rho = 0.3487 p < 0.001; DBL4γ v 3D7
Spearman's rho = 0.4054 p < 0.001). These correlations
were maintained after accounting for previous exposure in
a multiple linear regression model. There were no correla-
tions observed between individual antibody responses
measured against any other recombinant domain and any
of the parasite lines tested.
Association of anti-A4PfEMP1 antibody responses and 
protection from clinical malaria
When antibody positivity to the PfEMP1 recombinant
domains was analysed as a whole within Chonyi, no asso-
ciation was found between antibody response and subse-
quent disease experience (Table 2). When individuals
were categorized by parasite status at the time of bleed, a
positive association between the presence of anti-DBL1α
antibodies and protection from subsequent clinical
malaria was found in those parasite negative at the time of
bleed. No association with protection from or susceptibil-
ity to malaria was observed with antibodies against any
other recombinant domain in Chonyi and antibody
responses to none of the domains were associated with
protection in Ngerenya.
Discussion
PfEMP1 is currently the most plausible and best character-
ized of the erythrocyte surface-expressed parasite-induced
proteins proposed as targets for naturally acquired protec-
tive immune responses [31]. PfEMP1 is a large, diverse
and structurally complex molecule. It is composed of an
intracellular, highly conserved domain and a large, extra-
cellular variant domain. Although this extracellular
domain is highly polymorphic, PfEMP1 variants share an
overall common structure.
It has been hypothesized that naturally acquired immu-
nity develops through the piecemeal acquisition of a large
repertoire of antibodies directed against variants of this
protein [8]. Supporting this possibility are experimental
vaccination of aotus monkeys with selected domains from
specific PfEMP1 variants resulting in protection against
Table 1: Effect of parasite status on antibody levels to each 
recombinant domain
Domain coefficient1 95% C.I. P-value
DBL1α 0.067 0.027 – 0.117 0.001
CIDR1α 0.044 0.015 – 0.072 0.003
DBL2β 0.074 0.029 – 0.118 0.001
DBL4γ -0.036 -0.078 – 0.006 0.1
DBL5β 0.002 -0.034 – 0.039 0.886
1Results from a multiple linear regression giving the coefficients for 
the effect of being parasite positive on the OD obtained to each 
domain, controlling for the confounding effects of age, location and 
exposure (as estimated by responses to schizont extract).
Proportion of individuals in each age group recognizing para- site line A4u Figure 3
Proportion of individuals in each age group recogniz-
ing parasite line A4u. Sera from 272 individuals older than 
six months, was tested for reactivity against the parasite line 
A4U using flow cytometry. The proportion of individuals in 
each age category, with upper 95% confidence interval, scor-
ing positive for antibody recognition are shown. Positivity 
was scored as defined in the text. The light grey bars repre-
sent individuals resident in Chonyi and the dark grey bars 
represent individuals resident in Ngerenya.
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the homologous genotype, [32], and more recent data
showing cross-protection against heterologous strains of
parasite after immunization with a DBL1α domain [33].
Understanding the naturally occurring antibody response
to the DBL and CIDR domains making up the extracellu-
lar component of a specific PfEMP1 protein is thus an
important part of evaluating the usefulness of PfEMP1 as
a vaccine candidate.
Recent publications exploring the dynamics of the natu-
rally acquired antibody response to PfEMP1 have shown
that whilst cross-reactive antibody responses to PfEMP1
molecules encoded by different parasite genomes must
exist; children in endemic areas acquire surface reactive
antibodies to most variant surface antigens [8], and these
have been associated with protection [34], there is little
evidence of any cross-reactivity in responses to PfEMP1
domains within a single genome [35]. Looking at
responses to specific domains, Lusingu et al found evi-
dence of protection associated with the presence of anti-
bodies directed against a recombinant CIDR1α expressed
from a large complex var  gene implicated in severe
malaria [36]. A further study has shown that antibodies
directed against recombinant domains from
PfEMP1expressed from an isogenic parasite line of 3D7
increase both with intensity and age and that specifically,
increased levels of anti-CIDR2β are associated with less
clinical malaria [37]. In addition, Oguariri and colleagues
compared the prevalence of antibodies directed against
recombinant DBL1α domains from nine wild isolates in
the sera of children and adults resident in an area hyper-
endemic for P. falciparum transmission. There was strong
correlation between the age of the patients and reactivity
against the recombinant DBL1α domains[38]. Here,
through the use of recombinant protein technology, the
naturally acquired antibody response to the extracellular
domains of A4 PfEMP1 in the sera of individuals resident
in two areas endemic for P. falciparum malaria but with
different transmission characteristics have been evaluated.
It is clear that there are differences in the total acquisition
of domain-specific antibodies and the time over which
such responses are acquired both between areas and
between domains. Previous studies have described an
increased prevalence of antibodies to blood-stage anti-
gens amongst individuals with detectable parasites at the
time of bleed [28-30]. A similar result was obtained in this
study with regard to responses to DBL1α, DBL2β and
CIDR1α, but not to DBL4γ or DBL5β. This is a curious
result as these recombinant domains were cloned from a
laboratory parasite clone, A4. It implies that young chil-
dren possess a degree of cross-reactive short-lived
PfEMP1-specific antibodies capable of recognizing indi-
vidual domains.
It is interesting that not only did responses to DBL4γ cor-
relate positively with individual responses to the intact
A4-parasitized erythrocyte, but that these responses were
also correlated with individual responses to an alternative
A4 variant expressing a more heterogenous group of var
genes on the erythrocyte surface and also to an unrelated
laboratory clone, 3D7 and a clinical isolate, P1. That these
correlations were not found with any other recombinant
domain nor related to previous exposure as far as could be
determined may suggest a cross-reactive or more con-
served epitope maintained within the expressed DBL4γ
protein.
Despite showing clear evidence of age and exposure
dependent acquisition of domain specific responses and
in addition demonstrating that those responses to DBL1α
and DBL4γ correlate with antibody responses to the intact
Table 2: Association of serum IgG levels to recombinant 
domains of PfEMP1 with clinical malaria in Chonyi, Kenya for the 
period October 2000 until March 2001
Chonyi Slide all n = 596
Antigen Odds Ratio p-value 95% C. I.
DBL1α 0.75 0.580 0.26 – 2.11
DBL2β 0.63 0.472 0.18 – 2.21
CIDR1α 0.71 0.365 0.33 – 1.50
DBL4γ 0.89 0.791 0.37 – 2.13
DBL5β 0.72 0.517 0.26 – 1.95
Chonyi Slide positive n = 197
Antigen Odds Ratio p-value 95% C. I.
DBL1α 0.75 0.580 0.26 – 2.11
DBL2β 0.63 0.472 0.18 – 2.21
CIDR1α 0.71 0.365 0.33 – 1.50
DBL4γ 0.89 0.791 0.37 – 2.13
DBL5β 0.72 0.517 0.26 – 1.95
Chonyi Slide negative n = 399
Antigen Odds Ratio p-value 95% C. I.
DBL1α 0.05 0.020 0.04 – 0.63
DBL2β 0.26 0.208 0.32 – 2.10
CIDR1α 0.72 0.553 0.25 – 2.10
DBL4γ 0.49 0.290 0.14 – 1.81
DBL5β 0.49 0.343 0.11 – 2.11
1Results from a multiple logistic regression giving the odds ratio for 
becoming a case of clinical malaria in the subsequent six months if 
scored as antibody positive against each domain in turn controlling for 
for age (categorized as a factor of six months duration) and exposure 
(estimated by responses to whole schizont extract). An individual was 
deemed antibody positive if the OD obtained was greater than the 
mean OD plus 3 standard deviations obtained from a panel of non-
exposed donors.Malaria Journal 2008, 7:155 http://www.malariajournal.com/content/7/1/155
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A4-parasitized erythrocyte, we were unable to convincing
correlation with protection from clinical disease. By
expressing each domain as a recombinant fusion protein
in  E. coli, it is likely that important conformational
epitopes will not be accessible to the sera tested or equally
that what is being recognized by sera are not important
targets within the host Whether these antibodies are react-
ing to epitopes exposed by the process of cloning and
expression within the bacterial system, epitopes not
exposed as part of the full A4 PfEMP1 molecule, or
whether this reflects methodological limitations within
the affinity purification process is presently unknown.
It is difficult to know how to interpret the apparent pro-
tective relationship between responses to DBL1α in para-
site negative individuals in the higher transmission setting
in this study. Previous studies in this area have shown an
important effect of parasite positivity on the ability to
detect protective responses against several blood stage
antigens [28-30]. Given that in this case the effect is in the
opposite direction, it must be considered that this is a
chance finding and unlikely to be biologically meaning-
ful.
Despite these limitations the data presented here have
demonstrated the presence of antibodies in human sera to
expressed domains of one variant of PfEMP1. An impor-
tant component of investigating PfEMP1 as a vaccine can-
didate will involve determining what role antibodies have
to both conserved and variable parts of this protein. The
finding of potential cross-reactive responses to the
domain DBL4γ in this work is potentially important and
further work is needed to further clarify these responses.
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